HARTFORD INSURANCE GROUP, INC.·4

Feb 4, 4:08 PM ET

Swift Christopher 4

4 · HARTFORD INSURANCE GROUP, INC. · Filed Feb 4, 2026

Research Summary

AI-generated summary of this filing

Updated

Hartford (HIG) CEO Christopher Swift Exercises Options and Sells Shares

What Happened

  • Christopher Swift, Chairman & CEO of Hartford Insurance Group (HIG), exercised 201,938 stock options (exercise price $48.89; total exercise cost reported $9,872,749) on Feb 2, 2026, and on the same day sold the 201,938 resulting shares in multiple open-market transactions for total proceeds of approximately $27.55M.
  • Sales were executed in several blocks at prices ranging roughly from $135.04 to $137.14 per share (individual blocks and proceeds listed below). The Form 4 also reports a derivative/conversion entry for 201,938 shares at $0.00 (recorded as a disposal).

Key Details

  • Transaction date: Feb 2, 2026; Form filed Feb 4, 2026.
  • Option exercise: 201,938 shares @ $48.89 = $9,872,749 (code M).
  • Sales (code S), all on Feb 2, 2026:
    • 7,598 sh @ $137.08 = $1,041,503
    • 7,845 sh @ $137.09 = $1,075,433
    • 19,734 sh @ $135.54 = $2,674,662
    • 19,834 sh @ $135.56 = $2,688,755
    • 73,390 sh @ $136.57 = $10,023,056
    • 73,537 sh @ $136.58 = $10,043,529
    • Total sold: 201,938 shares; total proceeds ≈ $27,546,938.
  • A separate derivative entry lists 201,938 shares disposed at $0.00 (reported as exercise/conversion/disposition).
  • Footnotes note the trades were executed under a Rule 10b5-1 trading plan adopted Nov 3, 2025; the exercised options were granted in 2017 and expire Feb 28, 2027.
  • Beneficial ownership after the transaction is not specified in the provided excerpt.
  • Filing appears timely (transactions 2/2/2026; Form filed 2/4/2026).

Context

  • This is an option exercise (M) followed by immediate open-market sales (S) of the same number of shares — a common pattern when executives exercise vested options and sell shares (often to cover exercise costs, taxes, or for diversification). The presence of a pre-established 10b5-1 plan indicates the sales were executed under a pre-set program, not necessarily a reactive trade.
  • Transaction codes: M = option exercise/conversion; S = sale. The $0.00 derivative disposal entry reflects how the exercise/conversion was reported on the Form 4, per the filing.

Insider Transaction Report

Form 4
Period: 2026-02-02
Swift Christopher
DirectorChairman and CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-02$48.89/sh+201,938$9,872,749396,754.948 total
  • Sale

    Common Stock

    [F1][F2]
    2026-02-02$137.08/sh7,598$1,041,503389,156.948 total
  • Sale

    Common Stock

    [F1][F3]
    2026-02-02$137.09/sh7,845$1,075,433381,311.948 total
  • Sale

    Common Stock

    [F1][F4]
    2026-02-02$135.54/sh19,734$2,674,662361,577.948 total
  • Sale

    Common Stock

    [F1][F5]
    2026-02-02$135.56/sh19,834$2,688,755341,743.948 total
  • Sale

    Common Stock

    [F1][F6]
    2026-02-02$136.57/sh73,390$10,023,056268,353.948 total
  • Sale

    Common Stock

    [F1][F6]
    2026-02-02$136.58/sh73,537$10,043,529194,816.948 total
  • Exercise/Conversion

    Stock Option

    [F7]
    2026-02-02201,938100,970 total
    Exercise: $48.89Exp: 2027-02-28Common Stock (201,938 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    40,003
  • Common Stock

    (indirect: By Trust)
    95,386
  • Common Stock

    (indirect: By Trust)
    60,865
  • Stock Option

    [F8]
    Exercise: $49.01Exp: 2029-02-26Common Stock (352,263 underlying)
    352,263
  • Stock Option

    [F9]
    Exercise: $51.87Exp: 2031-02-23Common Stock (310,820 underlying)
    310,820
  • Stock Option

    [F10]
    Exercise: $53.81Exp: 2028-02-27Common Stock (284,819 underlying)
    284,819
  • Stock Option

    [F11]
    Exercise: $55.27Exp: 2030-02-25Common Stock (327,679 underlying)
    327,679
  • Stock Option

    [F12]
    Exercise: $69.41Exp: 2032-02-23Common Stock (301,932 underlying)
    301,932
  • Stock Option

    [F13]
    Exercise: $78.28Exp: 2033-02-28Common Stock (248,933 underlying)
    248,933
  • Stock Option

    [F14]
    Exercise: $95.74Exp: 2034-02-27Common Stock (116,414 underlying)
    116,414
  • Stock Option

    [F15]
    Exercise: $116.41Exp: 2035-02-25Common Stock (99,403 underlying)
    99,403
Footnotes (15)
  • [F1]The transaction reported on this Form 4 was effected pursuant to a trading plan previously adopted by Mr. Swift on November 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The exercised options were granted to Mr. Swift in 2017 and are scheduled to expire on February 28, 2027.
  • [F10]The options became fully exercisable on February 27, 2021, the third anniversary of the grant date.
  • [F11]The options became fully exercisable on February 25, 2023, the third anniversary of the grant date.
  • [F12]The options became fully exercisable on February 23, 2025, the third anniversary of the grant date.
  • [F13]One-third of the options became exercisable on February 28, 2024, an additional one-third of the options became exercisable on February 28, 2025 and the remaining one-third of the options will become exercisable on February 28, 2026, the third anniversary of the grant date.
  • [F14]One-third of the options became exercisable on February 27, 2025, an additional one-third of the options will become exercisable on February 27, 2026 and the remaining one-third of the options will become exercisable on February 27, 2027, the third anniversary of the grant date.
  • [F15]One-third of the options will become exercisable on February 25, 2026, an additional one-third of the options will become exercisable on February 25, 2027 and the remaining one-third of the options will become exercisable on February 25, 2028, the third anniversary of the grant date.
  • [F2]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $137.04 - $137.14 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $137.04 - $137.13 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $135.04 - $135.89 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F5]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $135.04 - $135.93 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F6]Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $136.04 - $137.03 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F7]The options became fully exercisable on February 28, 2020, the third anniversary of the grant date.
  • [F8]The options became fully exercisable on February 26, 2022, the third anniversary of the grant date.
  • [F9]The options became fully exercisable on February 23, 2024, the third anniversary of the grant date.
Signature
Anthony J. Salerno, Jr., Attorney-in-Fact|2026-02-04

Documents

1 file
  • 4
    doc4.xmlPrimary